Literature DB >> 6758690

Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates.

K S Defever, W L Whelan, A L Rogers, E S Beneke, J M Veselenak, D R Soll.   

Abstract

Resistance to 5-fluorocytosine was studied in 137 independent Candida albicans clinical isolates. Seventy-eight isolates (57%) were susceptible; 51 isolates (37%) were partially resistant; 8 isolates (6%) were highly resistant. All partially resistant isolates gave rise to variants which were highly resistant. Some susceptible isolates gave rise to variants which were highly resistant; two such isolates were shown to be heterozygous for resistance, and these isolates define a new type of heterozygote. A partially resistant isolate gave rise to resistant variants which were auxotrophic for lysine; this result was interpreted as preliminary evidence that the allele which determined resistance was linked to an allele which determined auxotrophy for lysine. It is suggested that heterozygotes constitute a source of preexisting mutant alleles which determine resistance, and that 5-fluorocytosine treatment of infections due to heterozygotes may result in significant selection for resistant variants. A simple screening procedure is described by which partially resistant strains may be recognized.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6758690      PMCID: PMC185665          DOI: 10.1128/AAC.22.5.810

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Chemotherapy of systemic fungal diseases.

Authors:  P D Hoeprich
Journal:  Annu Rev Pharmacol Toxicol       Date:  1978       Impact factor: 13.820

2.  5-Fluorocytosine resistance in candida spp. and Torulopsis glabrata.

Authors:  J Schönebeck; S Anséhn
Journal:  Sabouraudia       Date:  1973-03

Review 3.  Chemotherapy of systemic mycoses (second of two parts).

Authors:  J E Bennett
Journal:  N Engl J Med       Date:  1974-02-07       Impact factor: 91.245

4.  Mode of action of 5-fluorocytosine and mechanisms of resistance.

Authors:  A Polak; H J Scholer
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

5.  Segregation of 5-fluorocytosine-resistance variants by Candida albicans.

Authors:  W L Whelan; E S Beneke; A L Rogers; D R Soll
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

6.  Clinical problems with 5-fluorocytosine.

Authors:  R J Holt
Journal:  Mykosen       Date:  1978-11

7.  Heterozygosity and segregation in Candida albicans.

Authors:  W L Whelan; R M Partridge; P T Magee
Journal:  Mol Gen Genet       Date:  1980

8.  Ploidy determination of Canadida albicans.

Authors:  A F Olaiya; S J Sogin
Journal:  J Bacteriol       Date:  1979-12       Impact factor: 3.490

9.  Natural heterozygosity in Candida albicans.

Authors:  W L Whelan; P T Magee
Journal:  J Bacteriol       Date:  1981-02       Impact factor: 3.490

10.  Further in vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

View more
  21 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  High-frequency switching in Candida albicans.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Red-pigmented Candida albicans in patients with cystic fibrosis.

Authors:  M L Kerkmann; M Schuppler; K D Paul; G Schoenian; M T Smith
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

4.  Genetic analysis of prototrophic natural variants of Candida albicans.

Authors:  A K Goshorn; S Scherer
Journal:  Genetics       Date:  1989-12       Impact factor: 4.562

5.  Complementation analysis of resistance to 5-fluorocytosine in Candida albicans.

Authors:  W L Whelan; D Markie; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

6.  In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus.

Authors:  H C Korting; M Ollert; A Georgii; M Fröschl
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

7.  Candida septic thrombosis of the great central veins associated with central catheters. Clinical features and management.

Authors:  W D Strinden; R B Helgerson; D G Maki
Journal:  Ann Surg       Date:  1985-11       Impact factor: 12.969

8.  Clinical efficacy of new α-bisabolol mouthwashes in postoperative complications of maxillofacial surgeries: a randomized, controlled, triple-blind clinical trial.

Authors:  Bruno Frota Amora-Silva; S C Ribeiro; C L Vieira; F R Mendes; A E Vieira-Neto; A P V Abdon; F N Costa; A R Campos
Journal:  Clin Oral Investig       Date:  2018-05-03       Impact factor: 3.573

9.  Development of resistance in candida isolates from patients receiving prolonged antifungal therapy.

Authors:  P Fan-Havard; D Capano; S M Smith; A Mangia; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 10.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.